1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk

IIDX:DVLA
1,580.00
IDR
+10.00
(+0.64%)
121.34EPS
12.57P/E
1.71TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
983.65
989.15
1,170.42
1,300.59
1,411.96
1,523.06
1,620.57
1,633.66
1,697.23
1,711.64
1,688.29
1,863.93
1,992.63
2,101.75
Basic EPS, GAAP
112.32
73.12
96.69
136.28
145.39
179.8
198.24
144.71
130.81
133.37
130.66
139.42
146.38
121.34
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
47
22.08
70
35
100
107
106.92
107
112
116
121
108
108
41
Book Value per Share
803.17
849.03
872.39
967.43
1,000.34
1,075.56
1,167.44
1,194.62
1,242.33
1,253.23
1,253.96
1,293.72
1,321.27
1,339.36
Tangible Book Value per Share
793.99
839.82
858.92
953.96
986.87
1,062.09
1,154
1,181.2
1,191
1,200.77
1,205.87
1,233.47
1,265.39
1,285.66
Basic Weighted Avg Shares
1,120
1,116
1,116
1,116
1,116
1,116
1,119
1,120
1,120
1,120
1,120
1,120
1,120
1,120
Sales/Revenue/Turnover
1,101,684
1,103,822
1,306,098
1,451,357
1,575,647
1,699,657
1,813,020
1,829,700
1,900,894
1,917,041
1,890,888
2,087,601
2,231,749
2,353,961
Operating Margin (%)
13.38
8.62
8.72
13.8
13.25
14.51
16.12
11.15
9.94
9.13
9.38
9.41
9.22
7.1
Depreciation Expense
11,935
13,000
14,327
16,599
23,031
24,561
26,989
31,850
35,724
33,122
35,440
36,628
41,272
42,145
Net Income, GAAP
125,796
81,598
107,894
152,083
162,249
200,652
221,783
162,073
146,505
149,375
146,336
156,147
163,947
135,906
Effective Tax Rate (%)
28.43
23.57
25.3
29.07
28.26
26.46
26.38
24.29
30.73
25.71
23.64
25.56
25.54
26.99
Profit Margin (%)
11.42
7.39
8.26
10.48
10.3
11.81
12.23
8.86
7.71
7.79
7.74
7.48
7.35
5.77
Working Capital
693,854
736,996
747,532
694,540
734,033
786,835
840,768
844,398
931,560
965,630
936,652
956,282
984,598
1,032,308
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,474
1,044
596
30
- -
Total Equity
899,546
947,455
973,517
1,079,580
1,116,300
1,200,262
1,306,079
1,337,974
1,391,412
1,403,621
1,404,432
1,448,973
1,479,826
1,500,083
Return on Invested Capital (%)
13.49
7.79
9.77
13.86
14.09
16.61
17.08
11.89
10.47
10.52
10.29
10.62
10.86
8.62
Return on Capital (%)
14.36
8.78
11.23
14.82
14.78
17.32
17.7
12.26
10.65
10.6
10.41
10.94
11.19
8.98
Return on Common Equity (%)
14.45
8.84
11.23
14.82
14.78
17.32
17.7
12.26
10.74
10.69
10.42
10.94
11.2
8.98

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
177
163
119
LT Borrowings
- -
- -
- -
LT Finance Leases
30
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,120
1,120
1,120
Market Capitalization
1,848,000
1,797,600
1,708,000

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,664,526
1,831,262
1,927,123
Cash, Cash Equivalents & STI
341,559
467,065
471,021
Accounts Receivable, Net
780,507
818,421
833,577
Inventories
448,007
443,399
542,952
Total Current Liabilities
679,929
780,931
894,814
Payables & Accruals
- -
- -
- -
ST Debt
177
163
119
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.33%
2.05%
2.13%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
5.69%
0.4%
5%
Sales/Revenue/Turnover
5.58%
4.14%
6.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
532,287
554,929
505,446
494,940
2,087,601
2025
544,293
541,807
- -
603,555
2,231,749
2026
594,799
613,799
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60.26
46.31
25.03
7.82
139.42
2025
70.42
38.01
- -
-0.34
146.38
2026
49.38
34.29
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
43
108
2025
- -
- -
- -
41
108
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ian Martin Wibawa Kloer
Full Time Employees
1,323
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Tower C Jakarta JK Indonesia 12430
IPO Date
Nov 11, 1994
Website
darya-varia.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PT Darya-Varia Laboratoria Tbk (DVLA.JK), a subsidiary of Blue Sphere Singapore Pte. Ltd., manufactures and markets pharmaceutical products and cosmetics primarily in Indonesia; it operates through four segments including Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company produces prescription medicines covering cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotics, women's healthcare, antiparasitics, vitamins and food supplements, antifungals, plastic surgery, general surgery, burn care, trauma wound management, aesthetic medicine, ear healthcare, and central nervous system disorders; consumer health offerings include skin nutrition under the Natur-E brand, respiratory products such as Decolgen, Allerin Expectorant, Decolsin, Neozep, Stop Cold, Silex, and Herbablend for nasal congestion, cough, and allergy-related breathing issues, multivitamins via Enervon-C, Enervon Active, Enervon Gold, and Supertin, vitamin C under Vicee, pediatric supplements like Imunped with zinc and vitamin C, Biogesic for pain relief, Diatabs antidiarrheal, and New Enzyplex for indigestion prevention. Founded in 1976 and headquartered in Jakarta, Indonesia, Darya-Varia maintains two c-GMP and BPOM-certified plants in Gunung Putri for soft gelatin capsules, liquids, plasters, ointments, and creams, and Citeureup for sterile injections, tablets, and capsules; it collaborates with affiliate PT Medifarma Laboratories at the Cimanggis Depok plant for toll manufacturing encompassing technology transfer, trials, stability studies, procurement, and commercial production of high-quality finished goods for domestic and export markets, with all products halal-certified. Recent developments include a July 2025 strategic marketing partnership with PT Eisai Indonesia for innovative gastrointestinal therapies to enhance patient access and portfolio expansion, a memorandum of understanding with PT Astra Komponen Indonesia for local medical device development, relaunch of the D-STAR 2025 scholarship for women researchers focusing on herbal innovations from Indonesian biodiversity, solid 2024 financial results with 10% net revenue growth to Rp2.09 trillion, and a planned IDR 209 billion 2024 capex largely for facility expansions, upgrades to GMP compliance, and product portfolio enhancements targeting 6-8% revenue growth in 2025.